Saladax Biomedical appoints Myslinski as CCO

Friday, November 16, 2012 12:18 PM

Saladax Biomedical, a Bethlehem, Penn.-based privately held company that develops diagnostic assays for the practical delivery of personalized medicine, has appointed Mark D. Myslinski as senior vice president and chief commercial officer.

Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations. Most recently he served as president and CEO of RedPath Integrated Pathology, where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.

Prior to his time at RedPath, Myslinski served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, and general manager, molecular and cellular diagnostics division of Veridex, both of which are Johnson & Johnson companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs